

10/524704
DT01 Rec'd PCT/PTC 14 FEB 2005

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Rowena V. Cube, et al.
Int'l Appln.
No. : PCT/US2003/026377
Int'l Date
Filed : 22 August 2003 (22/08/2003)
Serial No. : (To be assigned) Case No.: MS022YP
Filed : February 14, 2005
For : ACETOPHENONE POTENTIATORS OF
METABOTROPIC GLUTAMATE RECEPTORS

Commissioner for Patents
Alexandria, Virginia 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO-1449, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO-1449 after reviewing the pertinence of each reference.

EXPRESS MAIL CERTIFICATE
DATE OF DEPOSIT 2-14-2005
EXPRESS MAIL NO. EA 98958772643
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS
BEING DEPOSITED WITH THE UNITED STATES POSTAL
SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE"
ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO
COMMISSIONER FOR PATENTS, P.O. BOX 1450,
ALEXANDRIA, VIRGINIA 22313-1450.
MAILED BY Gabriele Crowley
DATE 2-14-05

This Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.


Pursuant to 37 CFR § 1.98(a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application are not enclosed herewith. Copies of the other references that are cited on the attached form PTO-1449 are enclosed herewith.

Pursuant to 37 CFR § 1.97(b), this Information Disclosure Statement is being filed within three months of the filing date of the present application.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Respectfully submitted,

By



J. Eric Thies

Reg. No. 35,382

Attorney for Applicant

MERCK & CO., Inc.

P.O. Box 2000

Rahway, New Jersey 07065-0907

(732) 594-3904

Date: February 14, 2005

(use as many sheets as necessary)

Sheet

1

of

2

Application Number

Filing Date**First Named Inventor**

Group Art Unit

Examiner Name

Attorney Docket Number

R.V. Cube et al

MS022YP

COMPLETE IN OWN

10-224704

BT01 Rec'd PCT/P 14 FEB 2005
February 14, 2005

[illegible][illegible]Examiner
SignatureDate
Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

COMPLETE IN FOLD

Application Number

Filing Date

First Named Inventor

Group Art Unit

Examiner Name

Attorney Docket Number

10,524,704

DTOT Rec'd PCT/F
 February 14, 2005

14 FEB 2005

R.V. Cube et al

MS022YP

Sheet

2

of

2

NON PATENT LITERATURE DOCUMENTS

Examiner
 Initials*

Cite
 No.

Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.

Bioorganic & medicinal Chemistry Letters 14 (2004) 5329-5332 "Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part 1: Identification and synthesis of phenyl-tetrazolyl acetophenones".

J. Med. Chem. 2004, 47, 4595-4599 "Phenyl-tetrazolyl Acetophenones: Discovery of Positive Allosteric Potentiators for the Metabotropic Glutamate 2 Receptor".

Examiner
 Signature

Date
 Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003